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Abstract
Imatinib was the first BCR-ABL-targeted agent approved for the treatment of patients with chronic
myeloid leukemia (CML) and confers significant benefit for most patients; however, a substantial
number of patients are either initially refractory or develop resistance. Point mutations within the
ABL kinase domain of the BCR-ABL fusion protein are a major underlying cause of resistance. Of
the known imatinib-resistant mutations, the most frequently occurring involve the ATP-binding
loop (P-loop). In vitro evidence has suggested that these mutations are more oncogenic with respect
to other mutations and wild type BCR-ABL. Dasatinib and nilotinib have been approved for second-
line treatment of patients with CML who demonstrate resistance (or intolerance) to imatinib. Both
agents have marked activity in patients resistant to imatinib; however, they have differential activity
against certain mutations, including those of the P-loop. Data from clinical trials suggest that
dasatinib may be more effective vs. nilotinib for treating patients harboring P-loop mutations. Other
mutations that are differentially sensitive to the second-line tyrosine kinase inhibitors (TKIs)
include F317L and F359I/V, which are more sensitive to nilotinib and dasatinib, respectively. P-loop
status in patients with CML and the potency of TKIs against P-loop mutations are key determinants
for prognosis and response to treatment. This communication reviews the clinical importance of
P-loop mutations and the efficacy of the currently available TKIs against them.
Background
Chronic myeloid leukemia (CML) accounts for approxi-
mately 20% of all adult leukemias in the United States [1].
Progression of CML is generally described as a three-phase
process, beginning in a mostly asymptomatic chronic
phase (CP), progressing to an intermediate accelerated
phase (AP) and followed by a usually terminal blast phase
(BP) [1]. Left untreated, CML usually progresses from CP
to BP over a period of 3 to 5 years [1].
CML is characterized by the Philadelphia chromosome,
which results from a genetic translocation between chro-
mosomes 9 and 22 [2,3]. This translocation results in
fusion of the BCR and ABL genes, which code for a consti-
tutively active BCR-ABL tyrosine kinase [4,5]. The activity
of this BCR-ABL tyrosine kinase, including its anti-apop-
totic effects, underlies the pathophysiologic basis of CML
[6-8].
Modern treatment of CML relies upon tyrosine kinase
inhibitors (TKIs) directed against BCR-ABL. Imatinib
(Gleevec®, Novartis Pharmaceuticals Corporation, East
Hanover, NJ, USA) was the first TKI approved for the treat-
ment of CML and is the current first-line treatment.
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Approval of this agent was based on data from the Inter-
national Randomized Study of Interferon and STI571
(IRIS) [9]. While most patients benefit from imatinib
treatment, a substantial number either are initially refrac-
tory (primary resistance) or develop resistance during the
course of treatment (acquired resistance). As a result of
primary resistance to imatinib, 24% of patients in IRIS
failed to achieve a complete cytogenetic response (CCyR)
after 18 months [9]. Additionally, secondary resistance
manifested as progression to advanced phases in 7% of
patients and as relapsed disease in approximately 17% of
patients [10].
Several underlying mechanisms of imatinib resistance
have been identified. One major cause is the presence of
point mutations within the ABL kinase domain of BCR-
ABL. Such mutations inhibit the ability of imatinib to
bind to BCR-ABL by corrupting the binding sites or pre-
venting the kinase domain from assuming the inactive
conformation required for imatinib binding [11]. Point
mutations develop in approximately 35% to 70% of
patients displaying resistance to imatinib, either sponta-
neously or through the evolutionary pressure of imatinib
[12,13].
More than 40 distinct resistance-conferring mutations
have been detected; the majority fall within four regions
of the kinase domain: the ATP-binding loop (P-loop) of
the ABL kinase domain, the contact site, the SH2 binding
site (activation loop), and the catalytic domain [14].
Approximately 85% of all imatinib-resistant mutations
are associated with amino acid substitutions at just seven
residues (P-loop: M244V, G250E, Y253F/H and E255K/V;
contact site: T315I; and catalytic domain: M351T and
F359V) [15]. The most frequently mutated region of BCR-
ABL is the P-loop, accounting for 36% to 48% of all muta-
tions [12,13].
The importance of P-loop mutations is further underlined
by in vitro evidence suggesting that these mutations are
more oncogenic with respect to unmutated BCR-ABL as
well as other mutated variants [16]. In various biological
assays, P-loop mutants Y253F and E255K exhibited an
increased transformation potency relative to unmutated
BCR-ABL. Overall, the relative transformation potencies
of various mutations were found to be as follows: Y253F
> E255K > native BCR-ABL ≥ T315I > H396P > M351T.
Transformation potency also correlated with intrinsic
BCR-ABL kinase activity in this study.
Two agents are currently approved for second-line treat-
ment of patients with CML who demonstrate resistance
(or intolerance) to imatinib: dasatinib and nilotinib
[17,18]. While both agents have marked activity in
patients resistant to imatinib, they are differentially effica-
cious against certain mutations, including those of the P-
loop. Data from clinical trials suggest that dasatinib may
be more effective than nilotinib in treating patients har-
boring P-loop mutations. This communication reviews
the clinical importance of P-loop mutations and the effi-
cacy of the currently available TKIs against them.
P-loop mutations and the response to imatinib
The mutations conferring resistance to imatinib have been
well characterized [11]. The mutation analysis have been
done using denaturing high-performance liquid chroma-
tography and direct sequencing [15]. In the GIMEMA
study, mutations were found in 43% of evaluable patients
(127 of 297 patients). Among them, mutations were
found in 27% with chronic phase patients, 52% of AP
patients, and 75% of myeloid BC, and 83% lymphoid BC/
Ph+ ALL [15]. The frequency of p-loop mutations clearly
increases in accelerated phase and blast crisis as well as
with disease duration [11,15]. Therefore patients with
CML in these phases tend to develop imatinib-resistant
mutations. Selection of resistant clones during therapy
and clonal cytogenetic evolution with longer duration
may be responsible for the development and expansion of
the resistant clones with the mutations. These mecha-
nisms argue against high-sensitivity mutation screening of
all CML patients before therapy. It is prudent to do muta-
tion analysis for patients who failed imatinib or have
advanced CML.
As mentioned previously, the most widely studied and
clinically dominant mechanisms of imatinib resistance
involve acquired point mutations within the kinase
domain of BCR-ABL. BCR-ABL mutants can be grouped
based on imatinib sensitivity: sensitive (IC50 ≤ 1000 nM);
intermediately sensitive (IC50  ≤ 3000 nM; ie, M244V,
G250E, Q252H, F317L and E355G); and insensitive (IC50
> 3000 nM; ie, Y253F/H, E255K/V and T315I). The vari-
ous mutations occur at different frequencies and confer
different levels of imatinib resistance (Fig. 1) [19].
The sensitivity of imatinib to many of these point muta-
tions has been studied in vitro (Table 1). BCR-ABL
mutated at the P-loop is 70-fold to 100-fold less sensitive
to imatinib compared with native BCR-ABL. The presence
of these mutations also has been associated with poor
prognosis for patients receiving imatinib. Indeed, before
the availability of second-line TKIs, patients with P-loop
mutations treated with imatinib alone experienced
reduced response and survival rates [12,13,20]. For exam-
ple, Brandford et al. found that in patients with CP and AP
CML, P-loop mutations were associated with death in 12
of 13 patients (92%; median survival of 4.5 months) vs. 3
of 14 patients with mutations outside of the P-loop (21%;
median survival of 11 months) [12]. Similarly, Soverini et
al. found that among CP patients with P-loop mutations,Journal of Hematology & Oncology 2008, 1:15 http://www.jhoonline.org/content/1/1/15
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8 of 9 patients experienced disease progression to AP or
BC after a median of 9 months from mutation detection
and 12 months from the onset of imatinib [20]. Only 3 of
9 patients with mutations outside of the P-loop experi-
enced disease progression to AP or BC. Deaths also were
reported more frequently with P-loop mutations (6 of 9
patients compared with 1 of 9 patients). Similarly, Nico-
lini et al. observed that among 89 patients with CML (64%
CP) after a median follow-up of 39.2 months since imat-
inib initiation, overall survival was significantly worse for
those with P-loop mutations (28.3 months) compared
with other mutations (not reached) [21]. Furthermore, a
recent study found that P-loop mutations were detectable
2.8 months before the development of resistance in
patients taking imatinib compared with 6.3 months for
T315I mutations, 10.8 months for M351T mutations, 2.9
months for A-loop mutations and 8.7 months for other
mutations [22]. Additionally, of the 7 patients with muta-
tions that were not detectable before relapse, 6 (86%) had
P-loop mutations. Taken together, this information high-
lights the increased rate of progression associated with P-
loop mutations. Because the appearance of such muta-
tions seems to indicate impending relapse and resistance
to imatinib, earlier detection may provide clinical benefit
for patients by prompting earlier reconsideration of ther-
apeutic interventions [22].
In contrast, other studies in which patients were permitted
to switch to second-line treatment showed no significant
prognostic differences between patients carrying P-loop
mutations vs. those with other mutations within BCR-ABL
[13,23]. This result may be due to the availability of newer
TKI therapies with greater activity against mutations of the
P-loop for imatinib-resistant patients (Table 2). Alterna-
tively, it is possible that the results of this study were influ-
enced by differences in the specific P-loop mutations
harbored by patients included in each study and/or differ-
ences in definition of the P-loop mutations may have con-
tributed to different outcomes. With regard to the latter,
Jabbour et al. defined P-loop mutations as those at resi-
dues 244 through 255 [13], while others included only
mutations at residues 250 through 255 [12,20] or 248
through 255 [21].
As with all BCR-ABL mutants, P-loop mutations are
detected more frequently in late-stage disease. Interest-
ingly, advanced CML is an independent factor associated
with their development [12,13,15]. When Soverini et al.
examined the frequency and distribution of mutations
according to disease phase at the time of diagnosis, they
found that 52% of patients with AP CML and 75% of
those with BP CML had mutations, compared with only
27% of patients in CP [15]. They also noticed a preferen-
tial association of P-loop and T315I mutations with
advanced phase disease. This is not surprising, as support-
Frequency of BCR-ABL P-loop mutations detected in 177  clinical specimens Figure 1
Frequency of BCR-ABL P-loop mutations detected in 
177 clinical specimens. The positions of the P-loop amino 
acid residues were indicated. M-methionine; L-leucine; G-gly-





Table 1: Sensitivity of Bcr-Abl kinase domain P-loop mutants to imatinib, nilotinib and dasatinib
Ba/F3 cellular proliferation IC50 value
Imatinib (nM) Nilotinib (nM) Dasatinib (nM)
M244V P-loop 2000 38 1.3
G250E P-loop 1350 48 1.8
Q252H P-loop 1325 70 3.4
Y253F P-loop 3475 125 1.4
Y253H P-loop > 6400 450 1.3
E255K P-loop >5000 200 5.6
E255V P-loop > 6400 430 11
Imatinib: sensitive (≤ 1000 nM), intermediate (≤ 3000 nM), insensitive (> 3000 nM). Nilotinib: sensitive (≤ 150 nM), intermediate (= 150 nM to 450 
nM), insensitive (> 2000 nM). Dasatinib: sensitive (≤ 5 nM), intermediate (≤ 5 nM to 11 nM), insensitive (> 11 nM). (adapted from Ref. 11).
Sensitive
Intermediate sensitivity
InsensitiveJournal of Hematology & Oncology 2008, 1:15 http://www.jhoonline.org/content/1/1/15
Page 4 of 9
(page number not for citation purposes)
ing pre-clinical evidence has shown the increased onco-
genic potential of P-loop mutations [16].
Dasatinib
Dasatinib is a potent, orally active, dual BCR-ABL/Src-
family kinase inhibitor [24]. Initial approval of dasatinib
was based on data from the START (SRC/ABL Tyrosine
kinase inhibition Activity: Research Trials of dasatinib)
program, a series of multicenter, open-label phase 2 clin-
ical trials in imatinib-resistant or -intolerant patients with
CML or Philadelphia chromosome-positive acute lym-
phoblastic leukemia (Ph+ ALL). In the START-C trial,
dasatinib was evaluated in patients with CP CML who
were resistant or intolerant of imatinib [25]. A recent
update to this trial showed that following 24 months of
treatment, dasatinib 70 mg twice daily was associated
with a high rate of durable cytogenetic responses in
patients with CP CML who were resistant or intolerant to
imatinib (Table 3) [26]. After 24 months of treatment, the
major cytogenetic response (MCyR) rate was 62% and
responses were durable with 88% of patients maintaining
their response. The CCyR rate was 53% and the major
molecular response was 47%. Additionally, at 24 months,
progression-free survival was 80% (75% in imatinib-
resistant and 94% in imatinib-intolerant patients) and
overall survival was 94% (92% in imatinib-resistant and
100% in imatinib-intolerant patients) [26]. Marked activ-
ity also was noted in advanced disease [27,28].
Dasatinib was initially approved at a dosage of 70 mg
twice daily (with or without food) for all stages of CML.
The label has recently been updated such that 100 mg
once daily is now the recommended regimen in CP CML
[17]. This update was based on an open-label, dose-opti-
mization study in which patients were randomized
(1:1:1:1) to receive one of four dasatinib regimens: 100
mg once daily, 50 mg twice daily, 140 mg once daily or 70
mg twice daily [29]. The 100-mg, once-daily dosage dem-
onstrated equivalent efficacy compared with the previ-
ously recommended 70-mg twice-daily dosage and was
associated with fewer grade 3/4 adverse events (AEs; 30%
vs. 48%, respectively) [29]. Most significantly, the 100-mg
dose was associated with lower rates of pleural effusions
(7% vs. 16%) and grade 3/4 thrombocytopenia (22% vs.
37%). Most other AEs were mild to moderate (grades 1/2)
in severity and tended to resolve either spontaneously or
with supportive care. Additionally, fewer discontinua-
tions and dose modifications occurred in the 100-mg
once-daily arm compared with the 70-mg twice-daily arm.
Following results of this trial, the recommended starting
dose of dasatinib for imatinib-resistant or -intolerant
patients with CP CML was changed to 100 mg once daily
[17]. The 70-mg twice-daily dosage remains the recom-
mended starting dosage for patients with advanced phase
disease (AP/BP CML or Ph+ ALL).
The marked activity of dasatinib in patients resistant to
imatinib can be understood by noting its mechanism of
action. Due to structural differences from imatinib and
nilotinib, dasatinib is active against most of the imatinib-
related mutations that lead to resistance. Dasatinib binds
multiple conformations of BCR-ABL [30], unlike imatinib
and nilotinib [31,32]. The ability to bind both active and
inactive conformations of BCR-ABL may explain its
potent activity against most of the known imatinib-resist-
Table 2: Efficacy of dasatinib and nilotinib in patients with CP 
CML harboring specific mutations
CCyR rates, n/N (%)
Dasatinib Nilotinib
Any mutation 158/369 (43) 18/77 (23)
P-loop mutations 61/141 (43) NR
L248V NR 0/2 (0)
G250E 19/51 (37) 1/4 (25)
Y253F/H 12/23 (52) 0/8 (0)
E255K/V 8/24 (33) 0/6 (0)
T315I 0/20 (0) 0/4 (0)
F317L 1/14 (7) NR*†
F359C/V 14/27 (52) 0/10 (0)*
Dasatinib data are based on 1,093 patients with CP CML enrolled in 
clinical trials with dasatinib [36]. Nilotinib data are based on 280 
patients with CP CML enrolled in a phase 2 clinical trial with nilotinib 
[42].
*(Adapted from Ref. [45]).
†Considered a nilotinib-sensitive mutation (18 of 45 patients 
harboring nilotinib-sensitive mutations achieved CCyRs) [45].
CP: chronic phase. CML: chronic myeloid leukemia. CCyR: complete 
cytogenetic response. NR: not reported.
Table 3: Clinical responses to dasatinib and nilotinib in CML treatment
Patients McyR(%) CCyR (%) PFS (%) OS (%)
DAS NIL DAS NIL DAS NIL DAS NIL
Imatinib-resistant 55 48 NR 30 75 NR 92 NR
Imatinib-intolerant 78 47 78 35 94 NR 100 NR
All patients 62 48 53 31 80 NR 94 NR
MCyR: major cytogenetic remission; CCyR: complete cytogenetic remission; PFS: progression free survival; OS: overall survival; DAS: Dasatinib; 
NIL: nilotinib; NR: not reported [26,42].Journal of Hematology & Oncology 2008, 1:15 http://www.jhoonline.org/content/1/1/15
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ant kinase domain mutations, with the exception of T315I
[33]. Dasatinib is also more potent than imatinib, with
325-fold greater in vitro activity against unmutated BCR-
ABL [31]. The increased potency of dasatinib, combined
with its ability to bind multiple conformation of BCR-
ABL, produces significant efficacy in patients with CML
and Ph+ ALL. The sensitivity of BCR-ABL mutants to
dasatinib can be classified as sensitive (IC50 ≤ 5 nM), inter-
mediately sensitive (IC50 = 5 to 11 nM; ie, E255K/V and
F317L) and insensitive (IC50 > 11 nM; ie, T315I) (Table
1). T315I, a contact point mutation, is insensitive to all
currently approved BCR-ABL inhibitors [30,31,33-35]. P-
loop mutated BCR-ABL is generally sensitive or intermedi-
ately sensitive to dasatinib, with IC50 values falling in the
range of 1 to 11 nM [11].
Responses to dasatinib in patients with CP CML (n = 961)
have been assessed by baseline mutational status [36].
Equivalent CCyR rates were noted in imatinib-resistant
patients with P-loop mutations (61 of 141; 43%) and all
other patients, except those with T315I and F317L muta-
tions (140 of 336; 42%). In this study, no patients (0 of
20) with T315I mutations and only 7% (1 of 14) of
patients with F317L mutations achieved CCyRs. These
mutations are therefore insensitive to dasatinib. With
regard to individual P-loop mutations, CCyR rates were
similar to or above those of patients without mutated
BCR-ABL: G250E, 37% (19 of 51); Y253F/H, 52% (12 of
23); and E255K/V, 33% (8 of 24) (Table 2). Patients with
CP CML enrolled in the phase 2 START-C trial were also
evaluated by baseline mutational status [37]. The results
from this trial were similar to those above. One resistant
patient with a Q252H mutation was observed; however,
further data are needed to determine the sensitivity of this
mutation to dasatinib. Moreover, as this mutation is more
sensitive to dasatinib than E255K in vitro, it is probable
that patients with Q252H mutations would respond at
least as well as those with E255K/V. Based on the available
data, P-loop mutations are not likely to pose a significant
barrier to treatment with dasatinib.
Mutations have been shown to develop with dasatinib
exposure. In an in vitro mutagenesis study, nine dasatinib-
resistant mutations involving six residues were found.
However, only F317V and T315I were isolated at interme-
diate drug concentrations, and T315I was the only muta-
tion to be detected at maximal achievable plasma
concentrations [38]. In clinical studies, T315A/I, F317I/L
and V299L are the most frequent mutations associated
with dasatinib resistance [37,39-41]. In the phase 2
START-C trial of patients with CP disease, new mutations
were detected in 11% of patients (22 of 201), including
6% (13 of 201) with T315A/I, F317L or V299L (4 of 201,
7 of 201 and 2 of 201 patients, respectively) [38]. Impor-
tantly, these mutations are uncommon at baseline.
Among all baseline mutations, F317L and T315I muta-
tions have been detected with frequencies of approxi-
mately 5% each [37]. T315A and V299L mutations were
not detected.
Nilotinib
Nilotinib is an analog of imatinib with 10-fold to 50-fold
greater potency against unmutated BCR-ABL than its par-
ent compound [35]. The approval of nilotinib was based
on the release of data from a single open-label phase 2
study of patients with CP or AP CML who were resistant
or intolerant to prior imatinib therapy [42,43].
In the phase 2 study, following at least 6 months of treat-
ment, rates of MCyR and CCyR rates were 48% and 31%,
respectively [42]. Among patients who achieved a MCyR,
96% continued treatment without progression or death
for at least 6 months (Table 3). In total, 11% of patients
discontinued treatment because of disease progression in
this study.
Most AEs were mild to moderate in severity and were gen-
erally able to be managed with dose reduction or interrup-
tion and appropriate supportive care. The most frequent
grade 3/4 AEs in patients with CP CML were neutropenia
(29%), thrombocytopenia (29%), asymptomatic serum
lipase elevation (14%) and bilirubin elevation (9%) [42].
In total, 15% of patients discontinued treatment as a
result of AEs [43]. Cross-intolerance was defined as the
reoccurrence of a grade 3/4 AE during nilotinib treatment
that caused the discontinuation of imatinib. Cross-intol-
erance to nilotinib occurred in 49% of patients with
hematologic intolerance to imatinib, mostly due to the
reoccurrence of thrombocytopenia [44]. In clinical trials,
nilotinib treatment has been associated with prolonga-
tion of the QTc interval, and sudden deaths have occurred,
which are likely related to ventricular repolarization
abnormalities. The prescribing information for nilotinib
carries a black box warning regarding the risk of these
events [18].
Nilotinib has clinical activity in patients with all BCR-ABL
mutations associated with imatinib resistance except
T315I [42]. However, accumulated evidence suggests that
nilotinib also possesses relative insensitivities to certain
BCR-ABL mutations. Ten nilotinib-insensitive BCR-ABL
mutations have been identified in vitro [38]. In contrast to
dasatinib, P-loop mutations are among the most resistant,
with IC50s ranging from 38 nM to 450 nM [11]. In a muta-
genesis study, the P-loop mutations Y253H and E255V
were persistent at intermediate drug concentrations and,
as with dasatinib, only T315I was isolated at maximal
achievable plasma concentrations [38].Journal of Hematology & Oncology 2008, 1:15 http://www.jhoonline.org/content/1/1/15
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In the key phase 2 study, no CCyRs were observed in
patients harboring L248V, Y253H or E255K/V mutations
[42]. Additionally, patients with G250E mutations had a
CCyR rate of 25%, which is lower than that in the overall
population (30%). In another study in patients with CP
CML receiving nilotinib, no patients with F359C/V muta-
tions experienced a CCyR [45] (Table 2). Y253H and
E255K/V mutations are also among those that develop
most frequently during nilotinib therapy and have been
linked to disease progression [46]. Y253H, E255K/V and
F359C mutations occurred in 8% of those assessed for
baseline mutations (23% of all mutations). These muta-
tions were associated with disease progression in 50% of
cases [45]. Among patients with AP CML, the same muta-
tions were associated with disease progression in 64%
[47]. Notably, the incidences of nilotinib-resistant muta-
tions at baseline and at progression are higher than those
for dasatinib-resistant mutations. The P-loop mutations
E255K/V, Y253H and F359C/V accounted for 25% (26 of
104) of all baseline mutations [45]. Furthermore, among
40 imatinib-resistant patients who developed mutations
during nilotinib therapy, 22 (55%) had newly detectible
mutations of the P-loop (10 [25%] with E255K/V; 7
[18%] with G250E; and 5 [13%] with Y253H).
Future agents
Because none of the currently available TKIs are effective
against T315I mutations, there is a clear need to develop
alternative options for patients with such mutations. Sev-
eral agents are in clinical development, including novel
TKIs and aurora kinase inhibitors.
Bosutinib (SKI-606) is a dual Src/Abl TKI with 200-fold
greater potency than imatinib against BCR-ABL in bio-
chemical assays [48]. Bosutinib is currently being evalu-
ated in a phase 3 trial of patients with CP CML.
Unfortunately, in vitro studies have shown that bosutinib
is not active against T315I [49,50]. In a phase 1/2 study,
48 patients with CP CML who were imatinib resistant or
intolerant were treated with bosutinib 500 mg daily [51].
Of evaluable patients, 84% (16 of 19) achieved a com-
plete hematologic response (CHR), and MCyRs were
achieved in 52% (11 of 21). The most common grade 3/4
toxicities occurring in ≥ 5% of patients were thrombocyto-
penia (6%) and rash (6%). Diarrhea (69%), nausea
(44%), vomiting (19%), abdominal pain (13%) and rash
(13%) were the most common grade 1/2 toxicities. Given
that bosutinib has minimal activity against c-Kit and
platelet-derived growth factor receptors, it may be associ-
ated with a lower incidence of AEs related to the inhibi-
tion of these targets (eg, edema, muscle cramps, skin rash,
pigmentation, endocrine abnormalities, low-grade inhibi-
tion of normal hemopoiesis) than other TKIs [49,50].
In the phase 1/2 trials of bosutinib, 13 imatinib-resistant
mutations were identified in 32 patients. Preliminary
results showed CHR in 12 of 14 patients with non-P-loop
mutations and 3 of 3 patients with P-loop mutations.
MCyR was demonstrated in 5 of 11 patients with non-P-
loop mutations and 1 of 1 patient with P-loop mutations
[51].
Other agents in development that may prove useful
against T315I mutations include aurora kinase inhibitors.
One such aurora kinase inhibitor, MK-0457, was the first
agent to demonstrate clinical activity against the T315I
phenotype [52]. In the study of 14 currently evaluable
patients with CML, 11 had an objective (hematologic,
cytogenetic and/or molecular) response, including all 9
patients with the T315I mutation [53]. Recently, however,
clinical trials of MK-0457 were suspended due to cardio-
toxicity concerns. Trials of other aurora kinase inhibitors,
including PHA-739358 (phase 2), AP-24534 (phase 1)
and XL-228 (phase 1), are ongoing. In early-stage clinical
trials of PHA-739358, responses have been observed
among patients with T315I mutations [54]. AP-24534 and
XL-228 have demonstrated activity in cell culture and in
mice bearing xenograft tumors expressing T315I BCR-ABL
mutants [55,56]. A phase 1 open-label trial of XL-228 has
been initiated in patients with Ph+ leukemia, and clinical
trials of patients with drug-resistant CML are planned for
AP-24534.
Conclusion
P-loop mutations in the BCR-ABL gene account for nearly
half of all mutations [12,13]. The mutations impart
increased transformation potency with respect to other
mutations and wild type BCR-ABL. Furthermore, Y253H
and E255K/V are commonly present at baseline before
second-line treatment.
Dasatinib and nilotinib have differential activity against
certain mutations, including those of the P-loop. Clinical
resistance to dasatinib has been noted for T315I and
F317L mutations but not for P-loop mutations. Addition-
ally, P-loop mutations rarely emerge during dasatinib
treatment. Y253H or E255K/V are commonly associated
with clinical resistance to nilotinib and can develop dur-
ing treatment. Nilotinib resistance is also associated with
other mutations (ie, F359 and T315I).
Based on the currently available data, dasatinib may be a
suitable second-line therapy for patients resistant to imat-
inib and who harbor P-loop or F359 mutations, while
nilotinib may be an appropriate treatment option for
patients with F317L mutations. Clearly, additional treat-
ments are needed for patients harboring T315I. Currently,
such patients should be considered for allogeneic stem
cell transplantation or entry into a clinical trial.Journal of Hematology & Oncology 2008, 1:15 http://www.jhoonline.org/content/1/1/15
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